For citation purposes: Musto A, Chondrogiannis S, Ferretti A, Crepaldi G, Marzola MC, Rampin L, Pasini F, Rubello D. 18F-FDG PET/CT may detect early response to Imatinib mesylate in GISTs with exon 11 mutation: case report and critical review of literature. OA Molecular Oncology 2013 Feb 01;1(1):1.

Critical review

 
Emerging Technologies

18F-FDG PET/CT may detect early response to Imatinib mesylate in GISTs with exon 11 mutation: case report and critical review of literature

A Musto,, S Chondrogiannis, A Ferretti,, G Crepaldi, MC Marzola, L Rampin, F Pasini, D Rubello
 

Authors affiliations

(1) Department of Nuclear Medicine, Medical Physics, Radiology, Neuroradiology, PET/CT Centre, ‘Santa Maria della Misericordia’ Hospital, Via Tre Martiri 140, 45100 Rovigo, Italy

(2) Department of Medical Physics, ‘Santa Maria della Misericordia’ Hospital, Rovigo, Italy

(3) Department of Oncology, ‘Santa Maria della Misericordia’ Hospital, Rovigo, Italy

(4) Current address: Nuclear Medicine and Radiology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy

Corresponding author Email: domenico.rubello@libero.it

Abstract

Introduction

Gastrointestinal stromal tumours (GISTs) represent a major fraction of gastrointestinal sarcomas, frequently showing c-kit exon 11 mutations and associated with a good response to imatinib mesylate. Secondary resistance to imatinib has also been reported during therapy; therefore, clinicians need non-invasive tools for early assessment of treatment response due to traditional morphologic criteria [X-rays and computerized tomography (CT)] being unsuccessful.

We report upon a patient with GIST with exon 11 mutation showing excellent response to imatinib mesylate, only a few days after initiation of the therapy and persisting for 18 months of follow-up. Here we also provide a short review of the recent literature on this topic.

Conclusion

There is evidence that F-FDG PET18 and PET/CT could be used to optimally monitor c-kit inhibitor therapy in GISTs, detecting early responders, non-respon-ders and secondary resistance, there by allowing better patient management.

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)